Press Releases

Date	Title	PDF Version
Dec 30, 2014	Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
Dec 15, 2014	Alexion Announces $500 Million Share Repurchase Program
Dec 10, 2014	Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
Dec 08, 2014	New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment
Nov 27, 2014	NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England
Nov 25, 2014	Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
Nov 15, 2014	Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
Nov 10, 2014	Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015
Nov 06, 2014	Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting
Oct 27, 2014	Alexion Launches Every Day with HPP™ Campaign in Support of Hypophosphatasia (HPP) Awareness Week

Search